Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the most promising stocks on our list.

TheFly reported on June 3 that BofA Securities analyst Jason Zemansky increased the price target on RCKT to $10 from $9 while maintaining a Buy rating on the shares. The analyst viewed the company’s first-quarter update positively, highlighting the restart of RP-A501 dosing as an important step in Rocket Pharmaceuticals’ near-term recovery strategy and development progress.

In a separate major operational milestone on June 12, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The voucher was awarded by the FDA in March 2026 following the approval of Kresladi, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I, a rare and potentially life-threatening immune disorder.

Before the transaction, RCKT reported cash, cash equivalents, and investments of $144.4 million as of March 31, 2026. Following the non-dilutive proceeds from the PRV sale, the company’s pro forma cash position increased to approximately $322.6 million, extending its expected operational runway through the second quarter of 2028.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company developing one-time gene therapies aimed at treating rare pediatric diseases, with a focus on potentially curative treatments and advancing toward commercialization.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.